For the first time in Moldova, the hemophiliacs will be able to administer the necessary doses of factor VIII or IX at home. There will be also performed operations on articulations. Starting with next year, 39 million lei will be allocated from the state budget for purchasing the necessary preparations. The sum is eight times higher than that allocated until now.

Hemophilia is a group of hereditary genetic disorders that impair the body's ability to control blood clotting or coagulation. The main treatment for hemophilia is called replacement therapy. Concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly dripped or injected into a vein. These infusions help replace the clotting factor that is missing or low.

Contacted by IPN, university lecturer Ion Corcimaru, Doctor Habilitate in Medicine, said that the factor type deficiency in blood and the individual necessary dose will be determined for every patient apart. The hemophiliacs will receive the dose needed for a week. The home treatment is prophylactic, aimed at preventing the development of complications.

Until now, the hemophiliacs in Moldova were unable to receive treatment at home as there were purchased limited quantities of factor. Preparations were administered only when the bleeding posed a danger to life. The quantity of factor VIII and IX is now 1.1 units per capote, but from 2014 will be 3 units, as in the European countries. The large quantities of factor will also enable to perform surgeries on articulations.

In Moldova there are about 240 hemophiliacs. They now need 85% of factor VIII and 15% of factor IX. The patients are currently treated only with factors obtained from plasma. In case of recombined coagulation factors, the danger of transmitting viral infections is reduced to a minimum.